PARP1 and cutaneous melanoma: This suggests that a deeper understanding of the underlying mechanisms of resistance and the role of DNA repair pathways could enhance the personalized application of PARP inhibitors, particularly in cutaneous melanoma where treatment options are limited and resistance to standard therapies is a barrier.